Oracle Wipro Pharmacovigilance Partnership
Analysis based on 8 articles · First reported Sep 22, 2026 · Last updated Sep 22, 2026
The partnership expands Oracle's cloud-based life sciences footprint and strengthens Wipro's pharmacovigilance service offering, a modest positive for both companies' competitive positioning. Oracle shares rose 2 percent in pre-market trading on the New York Stock Exchange, though the deal is unlikely to materially move broader markets.
Oracle Life Sciences, a unit of Oracle Corporation, announced a partnership with Wipro Limited to strengthen Wipro's pharmacovigilance service offering using Oracle's Argus business process services platform. The collaboration will help life sciences organizations accelerate deployment of drug safety operations with built-in compliance support. Wipro will integrate Argus into its AI-powered Wipro Intelligence suite to enhance case processing, reporting, regulatory submissions and post-marketing surveillance. Oracle said Argus business process services provides a cloud-based managed services model that enables scalable pharmacovigilance without the burden of maintaining on-premises systems. Wipro plans to use pre-configured Argus environments to speed customer onboarding and streamline safety workflows. Jasjit Singh, Managing Partner and Global Head of Business Process Services at Wipro Limited, said life sciences organizations are under increasing pressure to modernize safety operations while maintaining compliance and speed. Seema Verma, executive vice president and general manager of Oracle Health and Life Sciences, said the collaboration reflects growing demand for comprehensive, cloud-based pharmacovigilance solutions. In pre-market activity on the New York Stock Exchange, shares of Oracle were up 2.00 percent, changing hands at $151.57, after closing Monday's regular session 0.64 percent higher.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard